Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines

Immunology

Volumn 122, Issue 1, 2007, Pages 28-37

  He, Qing ^a,b   Martinez Sobrido, Luis ^c   Eko, Francis O ^b   Palese, Peter ^c   Garcia Sastre, Adolfo ^c   Lyn, Deborah ^b   Okenu, Daniel ^b   Bandea, Claudiu ^a   Ananaba, Godwin A ^d   Black, Carolyn M ^a   Igietseme, Joseph U ^a,b  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b MOREHOUSE SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d CLARK ATLANTA UNIVERSITY   (United States)

Author keywords

Chlamydia trachomatis; Delivery systems; Immunomodulation; Vaccines

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G2; OUTER MEMBRANE PROTEIN; SERYLPHENYLALANYLASPARTYLALANYLASPARTYLTHREONYLISOLEUCYLARGINYL ISOLEUCYLALANYLGLUTAMINYLPROLINE; SIALIDASE; THREONYLISOLEUCYLASPARAGINYLLYSYLPROLYLLYSYLGLYCYLTYROSYLVALYL GLYCYLLYSYLGLUTAMIC ACID; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHLAMYDIA; CHLAMYDIASIS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; GENE; GENITAL SYSTEM; HUMAN; HUMAN CELL; IMMUNITY; INFLUENZA VIRUS; LYMPHOID TISSUE; MUCOSA; NONHUMAN; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; T LYMPHOCYTE; TH1 CELL; VACCINATION; VIRUS RECOMBINANT;

ADMINISTRATION, INTRANASAL; ANIMALS; BACTERIAL VACCINES; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; DRUG DELIVERY SYSTEMS; FEMALE; GENETIC VECTORS; GENITAL DISEASES, FEMALE; GENITALIA, FEMALE; IMMUNITY, MUCOSAL; IMMUNODOMINANT EPITOPES; INFLUENZA A VIRUS; MICE; MICE, INBRED C57BL; MUCOUS MEMBRANE; TH1 CELLS; VACCINATION; VACCINES, SYNTHETIC;

EID: 34447294948     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2007.02608.x     Document Type: Article

References (49)

1. WHO. Global prevalence and incidence of selected curable sexually transmitted diseases. Overview and Estimates. Geneva : WHO, 1996 : 1996.
2. Paavonen J, Wolner-Hanssen P. Chlamydia trachomatis: a major threat to reproduction. J Hum. Reprod 1989 4 : 111 24.
3. Johnson RE, Newhall WJ, Papp JR, et al. Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections - 2002. MMWR Morb Mortal Wkly Rep (Recomm Rep) 2002 51 : 1 40.
4. Mahdi OS, Byrne GI, Kalayoglu M. Emerging strategies in the diagnosis, prevention and treatment of chlamydial infections. Expert Opin Ther Patents 2001 11 : 1253 65.
5. Bragina EY, Gomberg MA, Dmitriev GA. Electron microscopic evidence of persistent chlamydial infection following treatment. J Eur Acad Dermatol Venereol 2001 15 : 405 9.
6. De la Maza MA, De la Maza LM. A new computer model for estimating the impact of vaccination protocols and its application to the study of Chlamydia trachomatis genital infections. Vaccine 1995 13 : 119 27.
7. Igietseme JU, Eko FO, He Q, Bandea C, Lubitz W, Garcia-Sastre A, Black C. Delivery of Chlamydia vaccines. Expert Opin Drug Deliv 2005 2 : 549 62.
8. Morrison RP, Caldwell HD. Immunity to murine chlamydial genital infection. Infect Immun 2002 70 : 2741 51.
9. Loomis PW, Starnbach MN. T cell responses to Chlamydia trachomatis. Curr Opin Microbiol 2002 5 : 87 91.
10. Igietseme JU, Eko FO, He Q, Black CM. Antibody regulation of T-cell immunity: implications for vaccine strategies against intracellular pathogens. Expert Rev Vaccines 2004 3 : 23 34.
11. Cohen CR, Koochesfahani KM, Meier AS et al. Immunoepidemiologic profile of Chlamydia trachomatis infection: importance of heat-shock protein 60 and interferon-gamma. J Infect Dis 2005 192 : 591 9.
12. Morrison SG, Morrison RP. A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection. J Immunol 2005 175 : 7536 42.
13. Nelson DE, Virok DP, Heidi W et al. Chlamydia IFN-γ immune evasion is linked to host infection tropism. Proc Natl Acad Sci USA 2005 102 : 10658 63.
14. LaVerda D, Kalayoglu MV, Byrne GI. Chlamydial heat shock proteins and disease pathology: new paradigms for old problems? Infect Dis Obstet Gynecol 1999 7 : 64 71.
15. Stephens RS. Chlamydial genomics and vaccine antigen discovery. J Infect Dis 2000 S521 S23.
16. Kawa DE, Stephens RS. Antigenic topology of chlamydial PorB protein and identification of targets for immune neutralization of infectivity. J Immunol 2002 168 : 5184 91.
17. Murdin AD, Dunn P, Sodoyer R, Wang J, Caterini J, Brunham RC, Aujame L, Oomen R. Use of a mouse lung challenge model to identify antigens protective against Chlamydia pneumoniae lung infection. J Infect Dis 2000 181 (Suppl 3 S544 51.
18. Donati M, Sambri V, Comanducci M, Di Leo K, Storni E, Giacani L, Ratti G, Cevenini R. DNA immunzation with pgp3 gene of Chlamydia trachomatis inhibits the spread of chlamydial infection from the lower to the upper genital tract in C3H/HeN mice. Vaccine 2003 21 : 1089 93.
19. Sharma J, Bosnic AM, Piper JM, Zhong G. Human antibody responses to a Chlamydia-secreted protease factor. Infect Immun 2004 72 : 7164 71.
20. Belland RJ, Scidmore MA, Crane DD, Hogan DM, Whitmire W, McClarty G, Caldwell HD. Chlamydia trachomatis cytotoxicity associated with complete and partial cytotoxin genes. Proc Natl Acad Sci USA 2001 98 : 13984 9.
21. Slepenkin A, de la Maza LM, Peterson EM. Interaction between components of the Type III secretion system of Chlamydiaceae. J Bacteriol 2005 187 : 473 9.
22. Dong-Ji Z, Yang X, Shen C, Lu H, Murdin Am Brunham RC. Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP-ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune responses. Infect Immun 2000 68 : 3074 8.
23. Eko FO, He Q, Brown T et al. A novel recombinant multisubunit vaccine against Chlamydia. J Immunol 2004 173 : 3375 82.
24. Wu H-Y, Russell MW. Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system. Immunol Res 1997 16 : 187 201.
25. Igietseme JU, Uriri IM, Kumar SN, Ananaba GA, Ojior OO, Momodu IA, Candal DH, Black CM. Route of infection that induces a high intensity of gamma interferon-secreting T cells in the genital tract produces optimal protection against Chlamydia trachomatis infection in mice. Infect Immun 1998 66 : 4030 5.
26. Pal S, Theodor I, Peterson EM, de la Maza LM. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune respose against a genital challenge. Infect Immun 2001 69 : 6240 7.
27. Staats HF, Montgomery SP, Palker TJ. Intranasal immunization is superior to vaginal, gastric, or rectal immunization for induction of systemic and mucosal anti-HIV antibody responses. AIDS Res Hum Retroviruses 1997 13 : 945 52.
28. Efferson CL, Schickli J, Ko BK, Kawano K, Mouzi S, Palese P, Garcia-Sastre A, Ioannides CG. Activation of tumor antigen-specific cytotoxic T lymphocytes (CTLs) by human dendritic cells infected with an attenuated influenza A virus expressing a CTL epitope derived from HER-2/neu proto-oncogene. J Virol 2003 77 : 7411 24.
29. Knight SC, Iqball S, Woods C, Stagg A, Ward ME, Tuffrey M. A peptide of Chlamydia trachomatis shown to be a primary T-cell epitope in vitro induces cell-mediated immunity in vivo. Immunology 1995 85 : 8 15.
30. Stagg AJ, Elsley WAJ, Pickett MA, Ward ME, Knight SC. Primary human T-cell responses to the major outer membrane protein of Chlamydia trachomatis. Immunology 1993 79 : 1 9.
31. Ramsey KH, Soderberg LSF, Rank RG. Resolution of chlamydial genital infection in B-cell-deficient mice and immunity to reinfection. Infect Immun 1988 56 : 1320 5.
32. Garcia-Sastre A. Transfectant influenza viruses as antigen delivery vectors. Adv Virus Res 2000 55 : 579 97.
33. Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, Garcia-Sastre A. Rescue of influenza A virus from recombinant DNA. J Virol 1999 73 : 9679 82.
34. Ishizaki M, Allen JE, Beatty PR, Stephens RS. Immune specificity of murine T-cell lines to the major outer membrane protein of Chlamydia trachomatis. Infect Immun 1992 60 : 3714 8.
35. Allen JE, Locksley RM, Stephens RS. A single peptide from the major outer membrane protein of Chlamydia trachomatis elicits T cell help for the production of antibodies to protective determinants. J Immunol 1991 147 : 674 9.
36. Igietseme JU, Ananaba GA, Bolier J et al. Suppression of endogenous IL-10 gene expression in dendritic cells enhances antigen presentation for enhanced specific Th1 induction: potential for cellular vaccine development. J Immunol 2000 164 : 4212 9.
37. Tuffrey M, Alexander F, Woods C, Taylor-Robinson D. Genetic susceptibility to chlamydial salpingitis and subsequent infertility in mice. J Reprod Fertil 1992 95 : 31 8.
38. Kees U, Kynast G, Weber E, Krammer PH. A method for testing the specificity of influenz A virus-reactive memory cytotoxic T lymphocytes (CTL) clones in limiting dilution cultures. J Immunol Methods 1984 69 : 215 27.
39. Krammer PH, Dy M, Hultner L et al. Production of lymphokines by murine T cells grown in limiting dilution and long-term cultures. In : Fathman CG, Fitch FW, eds. Isolation, Characterization, and Utilization of T Lymphocyte Clones. New York : Academic Press, 1982 : 252 62.
40. Julkunen I, Melen K, Nyqvist M, Pirhonen J, Sareneva T, Matikainen S. Inflammatory responses in influenza A virus infection. Vaccine 2000 19 (Suppl 1 S32 37.
41. Matsuo K, Iwasaki T, Asanuma H, Yoshikawa T, Chen Z, Tsujimoto H, Kurata T, Tamura SS. Cytokine mRNAs in the nasal-associated lymphoid tissue during influenza virus infection and nasal vaccination. Vaccine 2000 18 : 1344 50.
42. Richey CM, Macaluso M, Hook EW. Determinants of reinfection with Chlamydia trachomatis. Sex Transm Dis 1999 26 : 4 11.
43. Veldhuijzen IK, Van Bergen JE, Gotz HM, Hoebe CJ, Morre SA, Richardus JH, Group PCS. Reinfections, persistent infections, and new infections after general population screening for Chlamydia trachomatis infection in the Netherlands. Sex Transm Dis 2005 32 : 599 604.
44. Parks KS, Dixon PB, Richey CM, Hook E Spontaneous clearance of Chlamydia trachomatis infection in untreated patients. Sex Transm Dis 1997 24 : 229 35.
45. Gonzalez-Aseguinolaza G, Nakaya Y, Molano A et al. Induction of protective immunity against malaria by priming-boosting immunization with recombinant cold-adapted influenza and modified vaccinia Ankara viruses expressing a CD8+-T-cell epitope derived from the circumsporozoite protein of Plasmodium yoelii. J Virol 2003 77 : 11859 66.
46. Influenza virus vaccine live intranasal - MedImmune vaccines: CAIV-T, influenza vaccine live intranasal. Drugs R D 2003 4 : 312 9.
47. Abramson JS. Intranasal, cold-adapted, live, attenuated influenza vaccine. Pediatr Infect Dis J 1999 18 : 1103 4.
48. Watanabe T, Watanabe S, Noda T, Fujii Y, Kawaoka Y. Exploitation of nucleic acid packaging signals to generate a novel influenza virus-based vector stably expressing two foreign genes. J Virol 2003 77 : 10575 83.
49. Couch RB. Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. N Engl J Med 2004 350 : 860 1.